AU2013200740A1 - Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease - Google Patents
Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease Download PDFInfo
- Publication number
- AU2013200740A1 AU2013200740A1 AU2013200740A AU2013200740A AU2013200740A1 AU 2013200740 A1 AU2013200740 A1 AU 2013200740A1 AU 2013200740 A AU2013200740 A AU 2013200740A AU 2013200740 A AU2013200740 A AU 2013200740A AU 2013200740 A1 AU2013200740 A1 AU 2013200740A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- inflammatory bowel
- disease
- bowel disease
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 55
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 27
- 229940124597 therapeutic agent Drugs 0.000 title claims description 11
- 239000004480 active ingredient Substances 0.000 title description 8
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 25
- 210000002429 large intestine Anatomy 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 15
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 15
- 208000025865 Ulcer Diseases 0.000 claims abstract description 12
- 231100000397 ulcer Toxicity 0.000 claims abstract description 12
- 208000002389 Pouchitis Diseases 0.000 claims abstract description 10
- 206010038063 Rectal haemorrhage Diseases 0.000 claims abstract description 10
- 230000000968 intestinal effect Effects 0.000 claims abstract description 10
- 208000009137 Behcet syndrome Diseases 0.000 claims abstract description 9
- JGCZBUBEWYTICT-UHFFFAOYSA-N 5-amino-5-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]pentane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(C(CC(O)CCO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 JGCZBUBEWYTICT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 19
- XXHKHLYABSAFDW-UHFFFAOYSA-N 5-amino-5-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]pentane-1,3-diol Chemical compound C1=C(Cl)C(C(CC(O)CCO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 XXHKHLYABSAFDW-UHFFFAOYSA-N 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 5
- 229960001940 sulfasalazine Drugs 0.000 claims description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- RUOPINZRYMFPBF-UHFFFAOYSA-N pentane-1,3-diol Chemical compound CCC(O)CCO RUOPINZRYMFPBF-UHFFFAOYSA-N 0.000 claims 1
- JTMVQBIJMXSDDD-UHFFFAOYSA-N pentane-1,3-diol hydrochloride Chemical compound Cl.CCC(O)CCO JTMVQBIJMXSDDD-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 14
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical class OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 12
- 230000000069 prophylactic effect Effects 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 54
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 description 24
- -1 cinnamyloxy group Chemical group 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 125000005843 halogen group Chemical group 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 206010009887 colitis Diseases 0.000 description 9
- 125000004953 trihalomethyl group Chemical group 0.000 description 9
- 102000003896 Myeloperoxidases Human genes 0.000 description 8
- 108090000235 Myeloperoxidases Proteins 0.000 description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 6
- 229960001265 ciclosporin Drugs 0.000 description 6
- 229930182912 cyclosporin Natural products 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229960001967 tacrolimus Drugs 0.000 description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000004849 alkoxymethyl group Chemical group 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001987 diarylethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229950006991 betamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical group [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases. The agent comprises a 2-amino-1,3-propanediol derivative 5 (e.g., 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3 propanediol hydrochloride) represented by the chemical formula (1) or a pharmaceutically acceptable salt or hydrate thereof: (Chemical formula 1) R, NH R2 X (CH2)n HOH (1) The agent is useful in the treatment or prevention of Crohn' s disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer and pouchitis. 4061990_1 (GHMatters) P78014.AU.1
Description
THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING 2-AMINO-1,3-PROPANEDIOL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE TECHNICAL FIELD 5 [0001] The present invention relates to a therapeutic agent for inflammatory bowel diseases that contains, as an active ingredient, 2-amino-1,3-propanediol derivative, a sphingosine-1-phosphate receptor agonist, or a pharmaceutically acceptable salt or hydrate 10 thereof. The presentinventionalsorelates toamethod for treating inflammatory bowel diseases. BACKGROUND ART [0002] Inflammatory bowel diseases, represented by Crohn's disease 15 and ulcerative colitis, are intractable diseases that often develop at relatively young ages and cause abdominal pain, fever, diarrhea, hematocheziaandothersymptoms. Crohn's disease isagranulomatous inflammatory disease of unknown cause that affects any part of the gastrointestinal tract from mouth to anus in a discontinuous manner. 20 The disease progresses from ulcer to fibrosis and stricture, involving all layers of the bowel wall from mucosa to serosa. It is associated with systemic symptoms such as abdominal pain, chronic diarrhea, fever and malnutrition. On the other hand, ulcerative colitis is characterized by diffuse nonspecific inflammation of 25 the large intestine of unknown cause. The disease primarily affects 1 4061990_1 (GHMattes) P78014.AU.1 mucosa and often forms erosions and ulcers. It is also associated with various systemic symptoms including bloody diarrhea. Inflammatory bowl disease also refers to other inflammatory disorders in small and large intestines, including intestinal 5 Behcet's disease, ulcerative colitis, bleeding rectal ulcer and pouchitis. Althoughitisbelievedthattheetiologyofinflammatory bowel diseases involves abnormal immune function, the exact cause of the diseases still remains unknown (Non-Patent Documents 1 and 2). 10 [0003] Medications for inflammatory bowel diseases include immunosuppressors, steroids, salazosulfapyridine and mesalazine. While immunosuppressors, in particular antimetabolites such as azathiopurine and 6-mercaptopurine, are considered effective 15 against Crohn's disease, the drugs exhibit low efficacy at an early stage of administration and often cause allergies, pancreatitis, leukopenia and other side effects. High doses of cyclosporine are effective against inflammatory and fistulous diseases, but the drug cannotbe used foraprolongedperioddue to its toxicity. Infliximab, 20 a monoclonal antibody that inhibits a tumor necrosis factor, is administered by intravenous infusion to treat moderate or serious Crohn's disease (especially those accompaniedby fistula) resistant to other treatments. However, long-term effects and side effects of the treatment are unknown. Other potential immunosuppressors 25 include interleukin-1 blockers, anti-interleukin-12 antibodies, 2 4061990_1 (GHMattes) P78014.AU.1 anti-CD4 antibodies, adhesive molecule inhibitors, and monoclonal antibodies against down-regulatory cytokines and tumor necrosis factors. Each of the current therapeutic approaches for the treatment of inflammatory bowel diseases has its own disadvantages. 5 Thus, there is a need for more effective and safe medications (Non-Patent Documents 3, 4 and 5). [0004] 2-amino-1, 3-propanediol derivatives described in the present application are known as effective immunosuppressors used to prevent 10 rejection in organ transplantation (Patent Literatures No. 1 and 2). While 2-amino-1,3-propanediol derivatives have been known to act as sphingosine-1-phosphate receptor agonists, their usefulness in the treatment of inflammatory bowel diseases has never been described. 15 [Non-Patent Document 1] 1997 Annual Report by the Research Committee of Intractable Inflammatory Bowel Disorders: The Ministry of Health and Welfare of Japan. [Non-Patent Document 2] New Engl J Med, 2002, 347: 417-429 [Non-Patent Document 3] Am J Gastroenterol, 2001, 96: 1977-1997 20 [Non-Patent Document 4] Nucl Med Commun, 2005, 26:649-655 [Non-Patent Document 5] Saishin Igaku 2004,59:1070-1075 [Patent Document 1] W02003/029184 Pamphlet [Patent Document 2] W02003/029205 Pamphlet DISCLOSURE OF THE INVENTION 25 PROBLEMS TO BE SOLVED BY THE INVENTION 3 4061990_1 (GHMattes) P78014.AU.1 [0005] It is an objective of the present invention to provide a therapeutic agent for the treatment of inflammatory bowel diseases that contains, as an active ingredient, a 2-amino-1,3-propanediol 5 derivative, orapharmaceutically acceptable salt or hydrate thereof. It is another objective to provide a method for treating inflammatory bowel diseases. MEANS FOR SOLVING THE PROBLEMS [0006] 10 The present inventors discovered that a 2-amino-1,3-propanediol derivative, a sphingosine-1-phosphate receptor agonist, or a pharmaceutically acceptable salt or hydrate thereof is useful in the treatment or prevention of inflammatory bowel diseases (Crohn's disease, Crohn's disease in large intestine, 15 intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer and pouchitis) and thus devised the present invention. [0007] Specifically, the present invention concerns the following: 1) A therapeutic or prophylactic agent for an inflammatory 20 bowel disease containing, as an active ingredient, a 2-amino-1,3-propanediol derivative represented by the chemical formula (1): [0008] (Chemical formula 1) 4 4061990_1 (GHMattem) P78014.AJ.1
(CH
2 )n OH (1) OH [0009] [whereinRi is a halogen atom, a trihalomethyl group, ahydroxy group, a lower alkyl group having 1 to 7 carbon atoms, a substituted or 5 unsubstituted phenyl group, an aralkyl group, a lower alkoxy group having 1 to 4 carbon atoms, a trifluoromethyloxy group, a phenoxy group, a cyclohexylmethyloxy group, a substituted or unsubstituted aralkyloxy group, a pyridylmethyloxy group, a cinnamyloxy group, a naphthylmethyloxy group, a phenoxymethyl group, a hydroxymethyl 10 group, a hydroxyethyl group, a lower alkylthio group having 1 to 4 carbon atoms, a lower alkylsulfinyl group having 1 to 4 carbon atoms, a lower alkylsulfonyl group having 1 to 4 carbon atoms, a benzylthio group, an acetyl group, a nitro group or a cyano group;
R
2 is a hydrogen atom, a halogen atom, a trihalomethyl group, a lower 15 alkoxy group having 1 to 4 carbon atoms, a lower alkyl group having 1 to 7 carbon atoms, a phenethyl group or a benzyloxy group; R 3 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkoxy group having 1 to 4 carbon atoms, a hydroxy group, a benzyloxy group, a lower alkyl group having 1 to 7 carbon atoms, a phenyl 20 group, a lower alkoxymethyl group having 1 to 4 carbon atoms or a lower alkylthio group having 1 to 4 carbon atoms; X is 0, S, SO or S02; and n is an integer from 1 to 4], or a pharmaceutically acceptable salt or hydrate thereof. 5 4061990_1 (GHMattes) P78014.AU.1 [0010] 2) The therapeutic or prophylactic agent for an inflammatory bowel disease according to 1), wherein the compound represented by the chemical formula (1) is 5 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3 propanediol. [0011] 3) The therapeutic or prophylactic agent for an inflammatory bowel disease according to 1), wherein the compound represented 10 by the chemical formula (1) is a hydrochloride of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3 propanediol. 4) The therapeutic or prophylactic agent for an inflammatory bowel disease according to 1) to 3), wherein the inflammatory bowel 15 disease is Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis. [0012] 5) A method for treating an inflammatory bowel disease, using 20 as an active ingredient a 2-amino-1,3-propanediol derivative represented by the chemical formula (1): [0013] (Chemical formula 2) 6 4061990_1 (GHMattes) P78014.AU.1 (CH 2 )n OH OH [0 0 14] [whereinRi is a halogen atom, a trihalomethyl group, ahydroxy group, a lower alkyl group having 1 to 7 carbon atoms, a substituted or 5 unsubstituted phenyl group, an aralkyl group, a lower alkoxy group having 1 to 4 carbon atoms, a trifluoromethyloxy group, a phenoxy group, a cyclohexylmethyloxy group, a substituted or unsubstituted aralkyloxy group, a pyridylmethyloxy group, a cinnamyloxy group, a naphthylmethyloxy group, a phenoxymethyl group, a hydroxymethyl 10 group, a hydroxyethyl group, a lower alkylthio group having 1 to 4 carbon atoms, a lower alkylsulfinyl group having 1 to 4 carbon atoms, a lower alkylsulfonyl group having 1 to 4 carbon atoms, a benzylthio group, an acetyl group, a nitro group or a cyano group;
R
2 is a hydrogen atom, a halogen atom, a trihalomethyl group, a lower 15 alkoxy group having 1 to 4 carbon atoms, a lower alkyl group having 1 to 7 carbon atoms, a phenethyl group or a benzyloxy group; R 3 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkoxy group having 1 to 4 carbon atoms, a hydroxy group, a benzyloxy group, a lower alkyl group having 1 to 7 carbon atoms, a phenyl 20 group, a lower alkoxymethyl group having 1 to 4 carbon atoms or a lower alkylthio group having 1 to 4 carbon atoms; X is 0, S, SO or S02; and n is an integer from 1 to 4], or a pharmaceutically acceptable salt or hydrate thereof. 7 4061990_1 (GHMattem) P78014.AJ.1 [0015] 6) The method for treating an inflammatory bowel disease according to 5), wherein the inflammatory bowel disease is Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's 5 disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis. [0016] 7) A therapeutic or prophylactic agent for an inflammatory bowel disease, comprising a 2-amino-1,3-propanediol derivative represented by the general formula (1): 10 [0017] (Chemical formula 3) NH R1 X (CH 2 )n OH (1) OH [0018] [whereinR ,is a halogen atom, a trihalomethyl group, ahydroxy group, 15 a lower alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted phenyl group, an aralkyl group, a lower alkoxy group having 1 to 4 carbon atoms, a trifluoromethyloxy group, a phenoxy group, a cyclohexylmethyloxy group, a substituted or unsubstituted aralkyloxy group, a pyridylmethyloxy group, a cinnamyloxy group, 20 a naphthylmethyloxy group, a phenoxymethyl group, a hydroxymethyl group, a hydroxyethyl group, a lower alkylthio group having 1 to 4 carbon atoms, a lower alkylsulfinyl group having 1 to 4 carbon atoms, a lower alkylsulfonyl group having 1 to 4 carbon atoms, a 8 4061990_1 (GHMatters) P78014.AU.1 benzylthio group, an acetyl group, a nitro group or a cyano group;
R
2 is a hydrogen atom, a halogen atom, a trihalomethyl group, a lower alkoxy group having 1 to 4 carbon atoms, a lower alkyl group having 1 to 7 carbon atoms, a phenethyl group or a benzyloxy group; R 3 is 5 a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkoxy group having 1 to 4 carbon atoms, a hydroxy group, a benzyloxy group, a lower alkyl group having 1 to 7 carbon atoms, a phenyl group, a lower alkoxymethyl group having 1 to 4 carbon atoms or a lower alkylthio group having 1 to 4 carbon atoms; X is 0, S, SO 10 orSO 2 ; andnisanintegerfrom1to4] orapharmaceuticallyacceptable salt or hydrate thereof, in combination of at least one therapeutic agent for an inflammatory bowel disease. [0019] 8) The therapeutic or prophylactic agent for an inflammatory 15 bowel disease according to 7), wherein the at least one therapeutic agent for an inflammatory bowel disease comprises a sulfasalazine, a steroid, or an immunosuppressor. ADVANTAGES OF THE INVENTION [0020] 20 According to the present invention, there is provided a therapeutic or prophylactic agent for inflammatory bowel diseases that contains, as an active ingredient, a diarylsulfide or diarylether derivative having a 2-amino-1, 3-propanediol structure, or a pharmaceutically acceptable salt or hydrate thereof. The 25 diarylsulfide or diarylether derivative acts as a 9 4061990_1 (GHMattes) P78014.AU.1 sphingosine-1-phosphate receptor agonist. There is also provided a method for treating or preventing inflammatory bowel diseases, including Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal 5 ulcer, or pouchitis. BEST MODE FOR CARRYING OUT THE INVENTION [0021] The 2-amino-1,3-propanediol derivatives of the present invention are sphingosine-1-phosphate receptor agonists and 10 comprise a group of compounds represented by the chemical formula (1) and pharmaceutically acceptable salts and hydrates thereof: [0022] (Chemical formula 4) R x RJ NH M2 OH(1 R 2
(CH
2 )n HOH (1 OH 15 [0023] [whereinRi is a halogen atom, a trihalomethyl group, ahydroxy group, a lower alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted phenyl group, an aralkyl group, a lower alkoxy group having 1 to 4 carbon atoms, a trifluoromethyloxy group, a phenoxy 20 group, a cyclohexylmethyloxy group, a substituted or unsubstituted aralkyloxy group, a pyridylmethyloxy group, a cinnamyloxy group, a naphthylmethyloxy group, a phenoxymethyl group, a hydroxymethyl group, a hydroxyethyl group, a lower alkylthio group having 1 to 10 4061990_1 (GHMattes) P78014.AU.1 4 carbon atoms, a lower alkylsulfinyl group having 1 to 4 carbon atoms, a lower alkylsulfonyl group having 1 to 4 carbon atoms, a benzylthio group, an acetyl group, a nitro group or a cyano group;
R
2 is a hydrogen atom, a halogen atom, a trihalomethyl group, a lower 5 alkoxy group having 1 to 4 carbon atoms, a lower alkyl group having 1 to 7 carbon atoms, a phenethyl group or a benzyloxy group; R 3 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkoxy group having 1 to 4 carbon atoms, a hydroxy group, a benzyloxy group, a lower alkyl group having 1 to 7 carbon atoms, a phenyl 10 group, a lower alkoxymethyl group having 1 to 4 carbon atoms or a lower alkylthio group having 1 to 4 carbon atoms; X is 0, S, SO or S02; and n is an integer from 1 to 4] [0024] The term "halogen atom" in the chemical formula (1) of the 15 presentinventionincludesafluorineatom, achlorineatom, abromine atom and an iodine atom. The term "trihalomethyl group" includes a trifluoromethyl group and a trichloromethyl group. Theterm"lower alkyl group having 1 to 7 carbon atoms" includes straight-chained or branched hydrocarbons having 1 to 7 carbon atoms, such as methyl, 20 ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl and heptyl. [0025] The term "substitutedor-unsubstitutedphenoxygroup" includes those in which the benzene ring has at any position a halogen atom, such as a fluorine atom, a chlorine atom, a bromine atom and an 25 iodine atom, a trifluoromethyl group, a lower alkyl group having 11 4061990_1 (GHMattes) P78014.AU.1 1 to 4 carbon atoms or a lower alkoxy group having 1 to 4 carbon atoms. The term "aralkyl group" as in "aralkyl group" and "aralkyloxy group" includes a benzyl group, a diphenylmethyl group, a phenethyl group and phenylpropyl group. The term "lower alkyl group" in "lower 5 alkoxy group having 1 to 4 carbon atoms," "lower alkylthio group having 1 to 4 carbon atoms," "lower alkylsufinyl group having 1 to 4 carbon atoms," and "lower alkylsulfonyl group having 1 to 4 carbon atoms" includes straight-chained or branched hydrocarbons having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl 10 and butyl. The term "substituted or unsubstituted aralkyl group" includes those in which the benzene ring has at any position a halogen atom, such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, a trifluoromethyl group, a lower alkyl group having 1 to 4 carbon atoms or a lower alkoxy group having 1 to 4 carbon 15 atoms. [0026] Examples of pharmaceutically acceptable salts of the compound of the chemical formula (1) of the present invention include acid-addition salts such as hydrochlorides, hydrobromides, acetates, 20 trifluoroacetates, methanesulfonates, citrates and tartrates. [0027] More specific examples of the compound of the general formula (1) are 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3 25 propanediol and hydrochlorides thereof. 12 4061990_1 (GHMattes) P78014.AU.1 [0028] The compounds of the general formula (1) of the present invention are described in, for example, W003/029184 pamphlet and W003/029205 pamphlet and can be produced by techniques described 5 in these publications. [0029] The thus-obtained compounds of the present invention or pharmaceutically acceptable salts and hydrates thereof are useful in the treatment of inflammatory bowel diseases. The therapeutic 10 agents of the present invention are administered systemically or topically and orally or parenterally. The compounds may be formulated as oral or parenteral preparations depending on their properties. Specifically, the active ingredients may be mixed with pharmaceutically acceptable carriers, excipients, binders, 15 diluents or other auxiliary agents and formulated as granules, powders, tablets, capsules, syrups, suppositories, suspensions, solutions and other dosage forms. While the compounds may be administered in different doses depending on their use, the weight, age and conditions of the patients, they are typically administered 20 in a single dose of 0.01 to 100mg/patient, preferably at a single dose of 0.1 to 5mg/patient, once to three times a day. [0030] These preparations may be used in combination with at least one drug used to treat inflammatory bowel diseases. Examples of 25 such drugs include sulfasalazines, steroids and immunosuppressors. 13 4061990_1 (GHMattes) P78014.AU.1 Examples of sulfasalazines include mesalazine, olsalazine, sulfasalazine and balsalazide. Examples of steroids include hydrocortisone, methylprednisolone, budesonide and betamethasone phosphate. Examples of immunosuppressors include azathioprine, 5 6-mercaptopurine, cyclosporine, tacrolimus, anti-TNF-a antibody and anti-a4 integrin antibody. [0031] Examples The present invention will now be described with reference 10 to examples. While these examples primarily concern 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3 propanediol hydrochloride (which may be referred to as "KRP-203," hereinafter), one of the compounds represented by the chemical formula (1), other compounds are also encompassed by the present 15 invention and the scope of the invention is by no means limited by these examples. Example 1 [0032] Therapeutic effects on dextran sodium sulfate-induced colitis in 20 mice Colitis was induced in BALB/C male mice by allowing animals to drinka5% aqueous solutionofdextransodiumsulfate (DSS) (average molecular weight = 5000) for 7 days [Kitajima, S. et. al., ExpAnim, Vol.49, No.1: 9-15 (2000)]. KRP-203 dissolved in distilled water 25 (at 0.01, 0.03 and 0.1 mg/kg) was orally administered once a day 14 4061990_1 (GHMattes) P78014.AU.1 for8 days, startingthedaybefore theadministrationofDSS solution. One group was administered distilled water as a placebo. [0033] 8 days after the start of the DSS period, mice were anesthetized 5 withdiethyletherandsacrificedbycervicaldislocation. Thelarge intestine (the segment from colon to anus) was removed from each animal. Becauseitis knownthattheingestionofDSSsolutioncauses colitis in mice that causes a decrease in the length of large intestine [Okayasu, I. et. al., Gastroenterology, Vol.98: 694-702 (1990)], 10 the length of the large intestine from the colon to anus was measured withacaliper. The large intestine was then cut open longitudinally to expose the lumen and the content was washed off with physiological saline. The specimens were assayed and compared for the activity of myeloperoxidase, a marker of inflammation in colitis [Grisham, 15 MB. et. al., Methods Enzymol, Vol.186: 729-742 (1990)]. [0034] The comparison of the length of large intestine is shown in Table 1. The results indicate that KRP-203 significantly reduced the colitis-induced decrease in the length of large intestine. 20 [0035] 15 4061990_1 (GHMattes) P78014.AU.1 Table 1: Reduction of the decrease in the length of large intestine by KRP-203 Groups tested Number of Samples Length of large intestine Placebo group 8 64. 7 ± . 7" 0.01 mg/kg KRP-203 group 10 67. 4 ± 1. 4 0.03mg/kg KRP-203 group 10 72. 7 ± 1. 5** 0.1mg/kg KRP-203 group 9 71. 4 ± 1.4* Normal group 4 84. 7 ± 2. 2 Data are given in average ± standard error. ## : p(0. 01 (Student's t-test on normal group) * p(O. 05 (Dunnett's test on placebo group) **: p(O. 01 (Dunnett's test on placebo group) [0 0 36] The results of the assay for myeloperoxidase activity in large intestine are shown in Table 2. The results indicate that KRP-203 5 significantly reduced the colitis-induced increase in the myeloperoxidase activity in large intestine. [0037] Table 2: Suppression of the increase in myeloperoxidase activity in large intestine by KRP-203 myeloperoxidase activity Groups tested Number of Samples (U/g protein) Placebo group 8 108. 2 ± 20. 7"1 0.01mg/kg KRP-203 group 10 55. 8 ± 16. 2* 0.03mg/kg KRP-203 group 10 36. 8 ± 5. 9** 0.1mg/kg KRP-203 group 9 44. 4 ± 6. 4** Normal group 4 5.0 ± 0. 1 Data are given in average standard error. : p(O. 01 (Aspin-Welch's t-test on normal group) * p(O. 05 (Dunnett's test on placebo group) ** p(O. 01 (Dunnett's test on placebo group) 16 40619901 (GHMatter) P78014.AU.1 [0038] DDS-induced colitis in mice is frequently used as a disease model of inflammatory bowel diseases in humans [Elson, CO. et. al., Gastroenterology, Vol.109: 1344-1367 (1995); Hibi, T. et. al., J 5 Gastroenterol, Vol.37: 409-417 (2002)]. Thus, these results demonstrate the usefulness of KRP-203 in the treatment of inflammatory bowel diseases. Example 2 [0039] 10 Comparative Example Several drugs are used in the treatment of inflammatory bowel diseases. Immunosuppressors, drugs used to prevent rejection in organ transplantation, are one such option. As with KRP-203, two representative immunosuppressors cyclosporine and tacrolimus were 15 examined for their effects. [0040] Cyclosporine was dissolved in soybean oil (at 10 and 30 mg/kg) and was orally administered once a day for 8 days, starting the day before the start of the DSS period. One group was administered 20 soybean oil as a placebo. The increase in the myeloperoxidase activity in large intestine was suppressed by 54% in the 10mg/kg group and by 73% in the 30mg/kg group as compared to the placebo group. [0041] 25 Tacrolimus was suspended in a 0.5% aqueous solution of 17 4061990_1 (GHMattes) P78014.AU.1 carboxymethylcellulose sodium (CMC-Na) (at 3 mg/kg) and was administered once a day for 8 days, starting the day before the start of the DSS period. One group was administered 0.5% aqueous CMC-Na solution as a placebo. The increase in the myeloperoxidase 5 activity in large intestine was suppressed by 37% in the 3mg/kg group as compared to the placebo group. [0042] The effect on DDS-induced colitis in mice was then compared between cyclosporine and tacrolimus, two representative 10 immunosuppressors, and KRP-203: The increase in the myeloperoxidase activity in large intestine was suppressed by administration of KRP-203 by 51% in the 0.01mg/kggroup, by 69%in the 0.03mg/kg group, and by 62% in the 0.1mg/kg group as compared to the placebo group (Table 2) . These results suggest that lesser doses of KRP-203 have 15 a comparable or greater therapeutic effect on inflammatory bowel diseases than cyclosporine and tacrolimus. Example 3 [0043] Effect of KRP-203 on IL-10 knockout mice 20 B6.129P2-IL10<tmicgn>/J (IL-10 knockout) mice (male, 5-6 week old) were obtained for the test. KRP-203 dissolved in distilled water was orally administered at a dose of 0.1mg/kg once a day for 4weeks, starting 8 weeks after the animals were obtained. One group was administered distilled water alone as a placebo. Following the 25 administration period, the animals were dissected to remove large 18 40619901 (GHMatter) P78014.AU.1 intestine, which was then fixed in formalin. Subsequently, tissue slices were prepared from the formalin-fixed large intestine and were stained with hematoxylin and eosin. The proximal, middle, and distal segments of the large intestine were then histologically 5 scored according to the standard procedure (BergDJ, et al., Gastroenterology, 123: 1527-1542 (2002)) . The scores for the three segments were added together to determine the histological scores for individual animals. The results are given in average ± standard error. 10 [0044] As shown in Table 3, the histological score was significantly lower in the group administered KRP-203 than in the placebo group, a demonstration that KRP-203 reduces colitis in IL-10 knockout mice. These results suggest that the test compound KRP-203 is effective 15 in the treatment of inflammatory bowel diseases. [0045] Table 3:HiStological Score Groups tested Number of Samples Histological Score Placebo group 8 4.1±1. 3 KRP-203 group 8 0. 3±0. 2* *; p(0. 05 vs placebo group (Mann-Whitney's test) Example 4 [0046] 20 Preparation Example : Capsule preparation (in one capsule) Composition 19 4061990_1 (GHMatters) P78014.AU.1 Compound (KRP-203) 0.1 mg D-mannitol 247.5 mg Magnesium stearate 2.5 mg Specifically, the compound of the present invention was mixed 5 with D-mannitol. Magnesiumstearate was then blended in the mixture to form a powdery mixture. This mixture was packaged in a capsule to make a capsule preparation. INDUSTRIAL APPLICABILITY [0047] 10 As set forth, the compound of the present invention proved highly effective in a disease model of inflammatory bowel diseases in humans and caused a significant reduction in the tissue lesion in knockout mice. Thus, the 2-amino-1,3-propanediol derivatives of the present invention and pharmaceutically acceptable salts and 15 hydrates thereof are useful in the treatment or prevention of inflammatory bowel diseases. Accordingly, the present invention provides a therapeutic andprophylactic agent for inflammatorybowel diseases including Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, 20 bleeding rectal ulcer and pouchitis, as well as a method for treating or preventing these diseases. [0048] It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission 25 that the publication forms a part of the common general knowledge 20 4061990_1 (GHMattes) P78014.AU.1 in the art, in Australia or any other country. 21 4061990_1 (GHMattes) P78014.AU.1
Claims (18)
1. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt 5 or a hydrate thereof in the manufacture of a medicament for the treatment of an inflammatory bowel disease.
2. The use according to claim 1, wherein the inflammatory bowel disease is Crohn's disease, Crohn's disease in large 10 intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis.
3. The use according to claim 1 or 2, wherein the compound is 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] 15 ethyl-1,3-propanediol hydrochloride.
4. The use according to any one of claims 1 to 3 wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis. 20
5. A method for treating an inflammatory bowel disease, using 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof. 25 22 4061990_1 (GHMattes) P78014.AU.1
6. The method according to claim 5, wherein the inflammatory bowel disease is Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis. 5
7. The method according to claim 5 or 6, wherein the compound is 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol hydrochloride. 10
8. The method according to any one of claims 5 to 7 wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
9. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] 15 ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof in combination with at least one therapeutic agent for an inflammatory bowel disease, in the manufacture of a medicament for the treatment of an inflammatory bowel disease. 20
10. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof in the manufacture of a medicament for the treatment of an inflammatory bowel disease, wherein the 25 medicament further comprises at least one therapeutic agent 23 4061990_1 (GHMattes) P78014.AU.1 for an inflammatory bowel disease.
11. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt 5 or a hydrate thereof in the manufacture of a medicament for the treatment of an inflammatory bowel disease, wherein the medicament is formulated for administration with at least one therapeutic agent for an inflammatory bowel disease. 10
12. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof in the manufacture of a medicament for the treatment of an inflammatory bowel disease, wherein the medicament when administered, is administered with at least 15 one therapeutic agent for an inflammatory bowel disease.
13. The use according to any one of claims 9-12, wherein at least one therapeutic agent for an inflammatory bowel disease comprises a sulfasalazine, a steroid, or an immunosuppressor. 20
14. Use of 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof in the treatment of an inflammatory bowel disease. 25 24 4061990_1 (GHMattes) P78014.AU.1
15. The use according to claim 14, wherein the inflammatory bowel disease is Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis. 5
16. The use according to claim 14 or 15, wherein the compound is 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-1,3-propanediol hydrochloride. 10
17. The use according to any one of claims 14 to 16, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
18. Use of a compound or a pharmaceutically acceptable salt or a 15 hydrate thereof for the treatment of an inflammatory bowel disease substantially as herein described with reference to the accompanying examples. 25 4061990_1 (GHMattes) P78014.AU.1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013200740A AU2013200740A1 (en) | 2006-02-06 | 2013-02-12 | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006-027883 | 2006-02-06 | ||
| AU2007213194A AU2007213194B9 (en) | 2006-02-06 | 2007-02-05 | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease |
| AU2013200740A AU2013200740A1 (en) | 2006-02-06 | 2013-02-12 | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007213194A Division AU2007213194B9 (en) | 2006-02-06 | 2007-02-05 | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013200740A1 true AU2013200740A1 (en) | 2013-03-07 |
Family
ID=47833459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013200740A Abandoned AU2013200740A1 (en) | 2006-02-06 | 2013-02-12 | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2013200740A1 (en) |
-
2013
- 2013-02-12 AU AU2013200740A patent/AU2013200740A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007213194B2 (en) | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease | |
| JP5536016B2 (en) | Method for effective use of medicine and method for prevention of side effect | |
| US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| BR112019018162A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | |
| KR20230024277A (en) | Combination treatment of liver failure | |
| AU2017321322A1 (en) | Compositions and methods for treatment of prostate cancer | |
| CA3183414A1 (en) | Combination treatment of liver disorders | |
| EP3716969A1 (en) | Pharmaceutical combination comprising lsz102 and alpelisib | |
| WO2018237174A2 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| WO2021048417A1 (en) | Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma | |
| US20230241071A1 (en) | Combination treatment of liver disorders | |
| AU2013200740A1 (en) | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease | |
| PL206268B1 (en) | Analgesic and anti-inflammatory compositions containing cox-2 inhibitors | |
| US20160166577A1 (en) | Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin | |
| EP4051257A1 (en) | Combination therapy having antioxydant properties | |
| WO2008153511A1 (en) | The use of disulfiram in the treatment of gastrointestinal system ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |